0Q15.IL - Abbott Laboratories
| Previous close | 100.65 |
| Open | 100.80 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 100.66 - 101.98 |
| 52-week range | 93.36 - 115.37 |
| Volume | |
| Avg. volume | 37,708 |
| Market cap | 180.223B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | 31.28 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.04 (2.00%) |
| Ex-dividend date | 13 Apr 2023 |
| 1y target est | N/A |
- Zacks
Top Stock Reports for Procter & Gamble, Bank of America & Abbott Laboratories
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Bank of America Corporation (BAC) and Abbott Laboratories (ABT).
- Zacks
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Abbott (ABT) closed at $101.66, marking a -0.94% move from the previous day.
- Zacks
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
- Motley Fool
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
Dividend Kings are among the most steady corporations on the market. While many businesses don't even last a decade, these companies have survived and thrived and raised their payouts for at least 50 consecutive years to become a member of this elite group. Case in point: Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns.
- Zacks
Abbott (ABT) Gains But Lags Market: What You Should Know
In the latest trading session, Abbott (ABT) closed at $102.82, marking a +0.8% move from the previous day.
- Zacks
Abbott (ABT) Gains As Market Dips: What You Should Know
Abbott (ABT) closed at $102 in the latest trading session, marking a +0.29% move from the prior day.
- Zacks
Abbott (ABT) Reports Upbeat Cardiomems Sensor Study Result
Abbott's (ABT) MONITOR-HF is the third randomized, controlled trial that will provide significant health benefits to indicated heart failure patients.
- Zacks
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Abbott (ABT) closed at $102.14, marking a -1.83% move from the previous day.
- Zacks
Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker
Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
- Yahoo Finance Video
FTC investigating baby-formula makers on suspected collusion
Yahoo Finance health care reporter Anjalee Khemlani discusses the ongoing investigation by the FTC of baby-formula makers, including Abbott Laboratories, Perrigo, and Nestle, on suspected collusion.
- Reuters
Judge tosses out some claims in Abbott baby formula litigation
Abbott Laboratories persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination. But the judge said the parents lacked standing to sue, saying they did not show which Abbott products or lots were contaminated, or that their children experienced symptoms.
- Zacks
Abbott (ABT) Expands in Electrophysiology With New FDA Nod
Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.
- Zacks
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval
Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.
- Zacks
Abbott (ABT) Down 1.7% Since Last Earnings Report: Can It Rebound?
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Reuters
Abbott Labs is sued over PediaSure height claims
NEW YORK (Reuters) -A New York City woman sued Abbott Laboratories on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase children's height. In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller. The Bronx resident said that by February, after a year of two PediaSure drinks per day, her grandson was still short for his age and had become "so overweight" that she stopped buying the drinks.
- Zacks
Abbott's (ABT) New Pact to Advance Clinical Trials Diversity
Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.
- Zacks
Here's Why You Should Retain Abbott (ABT) Stock For Now
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
- Zacks
Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
- Zacks
Cigna (CI) Q1 Earnings Surpass Estimates, Ups '23 EPS View
Cigna's (CI) first-quarter 2023 results indicate a strong contribution to revenues from Evernorth Health Services and Cigna Healthcare businesses. Management currently expects adjusted EPS to be a minimum of $24.70 in 2023.
- Zacks
The Zacks Analyst Blog Highlights Berkshire Hathaway, Tesla, JPMorgan Chase, Abbott Laboratories and Comcast
Berkshire Hathaway, Tesla, JPMorgan Chase, Abbott Laboratories and Comcast are included in this Analyst Blog.
- Zacks
Acadia Healthcare (ACHC) Q1 Earnings Beat on Higher Patient Volumes
Acadia Healthcare's (ACHC) Q1 results reflect higher revenue per patient day, partly offset by an elevated cost level. Management reaffirms its 2023 business guidance.
- Motley Fool
Is Dexcom a Good Stock to Buy Now?
A poorly received first-quarter earnings report has investors wondering if this stock's best days are behind it.
- Motley Fool
Got $1,000? 2 Top Dividend Stocks to Buy Now
If you're looking to grow your $1,000, you can do that by investing in stocks that probably will deliver share performance. Let's check out two top Dividend Kings to buy now. You may know of Abbott because of its enormous COVID-19 testing business.
- Motley Fool
Why Abbott Laboratories Stock Looks Ridiculously Overpriced
Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. It benefited from COVID-related tests boosting its sales, but last year it ran into manufacturing issues that affected its baby formula production and hurt sales in its nutritional segment. The business is now getting back to normal, but the problem is that its valuation still needs to come down significantly before it's a worthwhile buy.
- Zacks
Centene (CNC) Q1 Earnings Miss Estimates, '23 EPS View Raised
Centene's (CNC) first-quarter 2023 results grapple with higher operating expenses, partly offset by an expanding customer base. Management presently expects adjusted EPS to be at least $6.40 in 2023.
